JP2023512648A5 - - Google Patents

Info

Publication number
JP2023512648A5
JP2023512648A5 JP2022545141A JP2022545141A JP2023512648A5 JP 2023512648 A5 JP2023512648 A5 JP 2023512648A5 JP 2022545141 A JP2022545141 A JP 2022545141A JP 2022545141 A JP2022545141 A JP 2022545141A JP 2023512648 A5 JP2023512648 A5 JP 2023512648A5
Authority
JP
Japan
Prior art keywords
glycoprotein
cov
immunogenic composition
composition according
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022545141A
Other languages
English (en)
Japanese (ja)
Other versions
JP7792339B2 (ja
JP2023512648A (ja
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed filed Critical
Priority claimed from PCT/US2021/015220 external-priority patent/WO2021154812A1/en
Publication of JP2023512648A publication Critical patent/JP2023512648A/ja
Publication of JP2023512648A5 publication Critical patent/JP2023512648A5/ja
Priority to JP2025184688A priority Critical patent/JP2026026092A/ja
Application granted granted Critical
Publication of JP7792339B2 publication Critical patent/JP7792339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022545141A 2020-01-27 2021-01-27 コロナウイルスワクチン製剤 Active JP7792339B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184688A JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US62/966,271 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US62/976,858 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US62/983,180 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US63/048,945 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US63/051,706 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US63/054,182 2020-07-20
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US16/997,001 2020-08-19
US202063129392P 2020-12-22 2020-12-22
US63/129,392 2020-12-22
PCT/US2021/015220 WO2021154812A1 (en) 2020-01-27 2021-01-27 Coronavirus vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184688A Division JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Publications (3)

Publication Number Publication Date
JP2023512648A JP2023512648A (ja) 2023-03-28
JP2023512648A5 true JP2023512648A5 (cg-RX-API-DMAC7.html) 2024-02-02
JP7792339B2 JP7792339B2 (ja) 2025-12-25

Family

ID=77079351

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022545141A Active JP7792339B2 (ja) 2020-01-27 2021-01-27 コロナウイルスワクチン製剤
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184688A Pending JP2026026092A (ja) 2020-01-27 2025-10-31 コロナウイルスワクチン製剤

Country Status (13)

Country Link
US (1) US12691171B2 (cg-RX-API-DMAC7.html)
EP (1) EP4097123A4 (cg-RX-API-DMAC7.html)
JP (2) JP7792339B2 (cg-RX-API-DMAC7.html)
CN (1) CN115720581A (cg-RX-API-DMAC7.html)
AU (1) AU2021214064A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022014830A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165371A1 (cg-RX-API-DMAC7.html)
GB (1) GB2610070A (cg-RX-API-DMAC7.html)
IL (1) IL295142A (cg-RX-API-DMAC7.html)
MX (1) MX2022009167A (cg-RX-API-DMAC7.html)
TW (1) TW202142555A (cg-RX-API-DMAC7.html)
WO (1) WO2021154812A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202401922B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
JP2024516309A (ja) * 2021-05-05 2024-04-12 ノババックス,インコーポレイテッド コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
WO2023025287A1 (zh) * 2021-08-26 2023-03-02 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
CN116808189A (zh) * 2021-10-22 2023-09-29 江苏瑞科生物技术股份有限公司 一种含有佐剂的新型冠状病毒免疫组合物及其应用
WO2023096990A1 (en) * 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CN102021147B (zh) 2003-03-24 2016-08-03 港大科桥有限公司 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用
CN1237184C (zh) 2003-06-03 2006-01-18 中国科学院上海药物研究所 抗SARS-CoV药物作用靶标、药物筛选方法及抗SARS药物
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
CN101939334B (zh) 2007-12-17 2015-01-14 医疗技术研究局 C型肝炎病毒抗体
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
CN102470168A (zh) 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
RU2403063C1 (ru) 2009-08-28 2010-11-10 Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота
CA2805741C (en) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2968510B1 (en) 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
CN103554244B (zh) 2013-05-09 2016-09-07 香雪集团(香港)有限公司 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法
EP3046579A1 (en) * 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
WO2015080973A1 (en) 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
JP6975709B2 (ja) 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化したウイルスクラスi融合タンパク質
CN114617959A (zh) * 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2017161151A1 (en) * 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2021147025A1 (en) 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法-sars-cov-2疫苗
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
KR20230054719A (ko) 2020-08-24 2023-04-25 사노피 파스퇴르 인크 Sars-cov-2 감염에 대한 백신
EP4313143A4 (en) 2021-03-22 2025-06-18 Novavax, Inc. Coronavirus vaccine formulations
JP2024516309A (ja) 2021-05-05 2024-04-12 ノババックス,インコーポレイテッド コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法

Similar Documents

Publication Publication Date Title
JP2026026092A5 (cg-RX-API-DMAC7.html)
JP5683811B2 (ja) キメラインフルエンザウイルス様粒子
Chroboczek et al. Virus-like particles as vaccine.
JP5917402B2 (ja) キメラRSV−Fポリペプチド、およびレンチウイルスGagまたはアルファレトロウイルスGagに基づくVLP
JP2024511412A5 (cg-RX-API-DMAC7.html)
TW202142555A (zh) 冠狀病毒疫苗配製品
JP2024516309A5 (cg-RX-API-DMAC7.html)
JP2008530245A5 (cg-RX-API-DMAC7.html)
JP2000515521A (ja) イヌの症状、特に呼吸器および消化器症状に対するポリヌクレオチドワクチン製剤
RU2018111760A (ru) Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
JP2015177808A (ja) Rsvfvlpならびにその製造および使用の方法
US11576960B2 (en) Respiratory syncytial virus (RSV) vaccines
CN120379690A (zh) 基于核酸的通用疫苗和其使用方法
JP2024530047A (ja) ワクチン抗原
CN117298264A (zh) 基于流感病毒ha蛋白和新冠病毒s蛋白的组合物和疫苗
TWI901715B (zh) 大猩猩腺病毒核酸及胺基酸序列,包含彼之載體,及其用途
US20070122430A1 (en) Influenza vaccine compositions and methods of use thereof
ES2353134T3 (es) Forma no escindible de la proteina gb de hcmv.
BRPI0811692A2 (pt) material com imunogenicidade
Kim et al. Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG)
CN117295516A (zh) 用于治疗hsv的疫苗组合物和方法
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
JPWO2002062381A1 (ja) バキュロウイルスベクターワクチン
WO2016059911A1 (ja) マラリアワクチン
AU2023330867A1 (en) Vaccines against coronaviruses